BL-8040: Phase IIa started

BioLineRx began the open-label, international Phase IIa COMBAT trial to evaluate 1.25 mg/kg subcutaneous BL-8040 with or without Keytruda pembrolizumab in up to 30 patients. In January, BioLineRx par...